GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Insider Ownership

CTOR (Citius Oncology) Insider Ownership : 0.00 % (As of Apr. 14, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Citius Oncology's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Citius Oncology's Institutional Ownership is 0.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Citius Oncology's Float Percentage Of Total Shares Outstanding is 7.69%.

Citius Oncology Insider Ownership Historical Data

The historical data trend for Citius Oncology's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Insider Ownership Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Insider Ownership
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Insider Ownership - - -

Citius Oncology Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Insider Ownership
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.